RedHill Biopharma (RDHL) announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Granted Nasdaq Compliance Extension
- RedHill Biopharma Gains FDA Support for Innovative Crohn’s Disease Therapy
- RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease
- RedHill Biopharma Initiates Phase 2 Prostate Cancer Study
- RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study